Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 55 points (-0.4%) at 14,948 as of Wednesday, Aug. 21, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 846 issues advancing vs. 2,101 declining with 78 unchanged. The Health Services industry currently sits down 0.3% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include Mindray Medical International ( MR), down 1.7%, Universal Health Services ( UHS), down 1.6%, Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.2%, Smith & Nephew ( SNN), down 1.1% and St Jude Medical ( STJ), down 1.0%. TheStreet would like to highlight 4 stocks pushing the industry higher today: 4. WuXi PharmaTech (Cayman ( WX) is one of the companies pushing the Health Services industry higher today. As of noon trading, WuXi PharmaTech (Cayman is up $0.77 (3.2%) to $24.86 on average volume. Thus far, 230,183 shares of WuXi PharmaTech (Cayman exchanged hands as compared to its average daily volume of 326,300 shares. The stock has ranged in price between $24.00-$25.00 after having opened the day at $24.12 as compared to the previous trading day's close of $24.09. Wuxi PharmaTech (Cayman) Inc., through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in China and the United States. It operates in two segments, Laboratory Services and Manufacturing Services. WuXi PharmaTech (Cayman has a market cap of $1.7 billion and is part of the health care sector. Shares are up 53.0% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate WuXi PharmaTech (Cayman a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates WuXi PharmaTech (Cayman as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full WuXi PharmaTech (Cayman Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.